Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04733118
Title Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedSIR

Her2-receptor positive breast cancer


Ado-trastuzumab emtansine

Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries ITA | ESP | DEU

No variant requirements are available.